Announcement PDF Market Announcement 16 June 2026 16 June 2026 Market Announcement 1/1 ASX Limited ASX Customer Service Centre 131 279 | asx.com.au Cynata Therapeutics Limited (ASX: CYP) – Suspension from Quotation The securities of Cynata Therapeutics Limited (‘CYP’) will be suspended from quotation immediately under Listing Rule 17.2 at the request of CYP, pending the release of an announcement by CYP. Unless ASX decides otherwise, the securities will remain suspended until the earlier of: • the end of the period stated in CYP’s request for voluntary suspension; or • the release of the announcement to the market. CYP’s request for voluntary suspension is attached below for the information of the market. Issued by ASX Compliance Cynata Therapeutics Limited Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia PO Box 7165, Hawthorn North, Victoria 3122 T: +613 7067 6940 E: info@cynata.com ABN – 98 104 037 372cytl0001_2100021_197.docx ASX ANNOUNCEMENT 16 June 2026 Ms Melissa Kostopoulos ASX Compliance Level 50, South Tower Rialto, 525 Collins Street Melbourne VIC 3000 By email: melissa.kostopoulos@asx.com.au Request for Voluntary Suspension Cynata Therapeutics Limited (“Cynata” or “the Company”) (ASX:CYP) requests a voluntary suspension of its quoted securities to apply from the open of trading today, Tuesday 16 June 2026. The voluntary suspension is requested pending material announcements by Cynata in relation to the results of the Phase 3 Osteoarthritis Trial (OA Trial) and Phase 2 Graft versus Host Disease Trial (GvHD Trial). Cynata expects to announce the results of the OA Trial and the GvHD Trial on or before Friday, 20 June 2026. In accordance with Listing Rule 17.2, Cynata provides the following information: (a) the voluntary suspension is requested pending the release by Cynata of the results of the OA Trial and the GvHD Trial; (b) the Company requests that the voluntary suspension remain in place until the earlier of the Company making announcements in relation to the OA Trial and the GvHD Trial and the commencement of trading on Friday, 19 June 2026; (c) the Company is not aware of any reason why the voluntary suspension should not be granted; and (d) the Company is not aware of any other information necessary to inform the market about the voluntary suspension. -ENDS- Authorised for release by the Board of Directors of Cynata Therapeutics Limited CONTACTS: Dr Kilian Kelly, CEO & MD,Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak,Media Contact,+61 (0)400 434 299, investors@cynata.com About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on thedevelopment of therapies based on Cymerus™, a proprietarytherapeutic stem cell platform technology.Cymerus™ overcomes thechallenges and limitationsofconventionalMSCproductionbyusinginducedpluripotentstemcells (iPSCs)to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs),at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods. Cynata has demonstrated positivesafety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further Cynata Therapeutics Limited Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia PO Box 7165, Hawthorn North, Victoria 3122 T: +613 7067 6940 E: info@cynata.com ABN – 98 104 037 372cytl0001_2100021_197.docx clinical trials are now ongoing:a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidneytransplantation;and a Phase3 trial of CYP-004 in osteoarthritis.In addition,Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonaryfibrosis,asthma, heart attack, sepsis,acute respiratory distress syndrome(ARDS) and cytokinerelease syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.